ASCO 2017 Congress Report


ASCO 2017 single articles:

EGFR-targeted treatments: insights from the adjuvant to the resistant setting
New standards of care for ALK-positive disease
Reducing the danger that arises from the CNS as a site of progression
Diagnostics of EGFR-mutant disease: biomarkers with significant clinical implications
Established targeted agents taking root in the HER2-positive setting
Further defining the optimal use of immune checkpoint inhibitors
Real-world utility of ctDNA NGS to identify matched targeted therapy
Interview: Lung cancer in China: hurdles and progress
Anti-angiogenic and immunotherapeutic approaches in mesothelioma
Enhancing the profile of KRAS-mutant lung cancer

Full Report (English)